Cargando…

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

BACKGROUND: Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related adverse events are now well described complications of PD-1 inhibitors and most or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Acero Brand, Fanny Zulay, Suter, Nicolas, Adam, Jean-Philippe, Faulques, Bernard, Maietta, Antonio, Soulières, Denis, Blais, Normand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857140/ https://www.ncbi.nlm.nih.gov/pubmed/29548299 http://dx.doi.org/10.1186/s40425-018-0332-z

Ejemplares similares

Plasma cell mucositis of the larynx
por: Smith, Jonathan G. F., et al.
Publicado: (2018)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world
por: Zhang, Pei, et al.
Publicado: (2022)

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
por: Harrington, Kevin J., et al.
Publicado: (2023)

Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design
por: Zheng, Yuyan, et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response
por: Wilkins, Matthew C, et al.
Publicado: (2021)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

The basaloid variant of squamous cell carcinoma of the larynx()
por: Tutar, Hakan, et al.
Publicado: (2014)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
por: Burtness, Barbara, et al.
Publicado: (2022)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome
por: Tos, Salem M., et al.
Publicado: (2022)

Combined small cell and squamous cell carcinoma of the larynx
por: Kołodziej, Paweł, et al.
Publicado: (2012)

Neoadjuvant Chemoradiotherapy and Larynx-Preserving Surgery for Cervical Esophageal Cancer
por: Dai, Kun-Yao, et al.
Publicado: (2020)

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)

Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System
por: Liu, Yuxin, et al.
Publicado: (2019)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
por: Kojima, Takashi, et al.
Publicado: (2022)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Metastatic Porocarcinoma Effectively Managed by Pembrolizumab
por: Singh, Arminder, et al.
Publicado: (2021)

Clinical Significance of Langerhans Cells in Squamous Cell Carcinoma of the Larynx
por: Esteban, Francisco, et al.
Publicado: (2012)

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
por: Zeng, Tian, et al.
Publicado: (2021)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Cellular DNA content and prognosis in surgically treated squamous carcinoma of the larynx.
por: Cooke, L. D., et al.
Publicado: (1991)

Euphorbia tirucalli modulates gene expression in larynx squamous cell carcinoma
por: Franco-Salla, Gabriela Bueno, et al.
Publicado: (2016)

Non-squamous cell carcinoma diseases of the larynx: clinical and imaging findings()()
por: Doğan, Serap, et al.
Publicado: (2019)

Thyroid gland invasion in advanced squamous cell carcinoma of the larynx and hypopharynx()()
por: Mangussi-Gomes, João, et al.
Publicado: (2016)

Basaloid squamous cell carcinoma of the larynx: A rare case report
por: Al-janabi, Moatasem Ali Hussein, et al.
Publicado: (2023)

Non-Squamous Cell Carcinoma of the Larynx: A State-of-the-Art Review
por: Chiesa-Estomba, Carlos M., et al.
Publicado: (2023)

Review of guidelines on the treatment of metastatic renal cell carcinoma
por: Soulières, D.
Publicado: (2009)

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Larynx organ preservation in subjects with hypopharynx-larynx cancer
por: Conticello, S, et al.
Publicado: (2010)

Comparing outcomes for endoscopic submucosal dissection between Eastern and Western countries: A systematic review and meta-analysis
por: Daoud, Dane Christina, et al.
Publicado: (2018)

Functional Larynx Preservation in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Treated With Induction Chemotherapy vs. Concurrent Chemoradiation Alone
por: Nehlsen, Anthony D, et al.
Publicado: (2021)

Metastatic squamous cell carcinoma of colon from esophageal cancer
por: Garg, Natasha, et al.
Publicado: (2017)

Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report
por: Dang, Harry, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rnmmmsjqpbi7j3e5u3dk3ljdai